-
公开(公告)号：US20200095984A1
公开(公告)日：2020-03-26
申请号：US16495487
申请日：2018-03-07
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Jacob Karni , Leon Karni
Abstract: The present invention relates to the utilization of solar energy for generation of electricity and/or production of clean fuels or other chemicals, as a means for long term, transportable storage of inherently intermittent solar energy.
-
82.发明授权公开(公告)号：US10557852B2
公开(公告)日：2020-02-11
申请号：US15307011
申请日：2015-04-28
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： David Margulies , Leila Motiei , Naama Mankovski , Yael Nissinkorn
Abstract: This invention is directed to monomolecular sensors, comprising a selective binder, a non-selective binder and a fluorophore, which can track changes that occur on the surface of labeled proteins. This invention is further directed to the use of such sensors for identifying binding partners of specific proteins. This invention is further directed to His-tag binding compounds and uses thereof in the preparation of genetically targeted detectable molecules and sensors which can specifically bind tag-labeled proteins.
-
公开(公告)号：US20190388064A1
公开(公告)日：2019-12-26
申请号：US16478507
申请日：2018-01-19
Inventor： Itay KEZURER , Achiau LUDOMIRSKY , Yaron LIPMAN
Abstract: An exemplary system, method and computer-accessible medium for detecting an anomaly(ies) in an anatomical structure(s) of a patient(s) can be provided, which can include, for example, receiving imaging information related to the anatomical structure(s) of the patient(s), classifying a feature(s) of the anatomical structure(s) based on the imaging information using a neural network (s), and detecting the anomaly(ies) based on data generated using the classification procedure. The imaging information can include at least three images of the anatomical structure(s).
-
公开(公告)号：US10468507B2
公开(公告)日：2019-11-05
申请号：US15527711
申请日：2015-11-19
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Oren Tal , Ran Vardimon , Marina Klionsky
IPC: H01L29/66 , B82Y25/00 , H01F1/00 , B82Y10/00 , H01L29/76 , H01L29/84 , H01L29/06 , H01F10/32 , H01L29/82
Abstract: The present invention is in the field of spintronics, and relates to a highly efficient spin filter device, such as a spin-polarizer or a spin valve, and a method for fabrication thereof.
-
公开(公告)号：US20190316087A1
公开(公告)日：2019-10-17
申请号：US16313486
申请日：2017-06-27
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair REISNER , Noga OR-GEVA , Rotem GIDRON BUDOVSKY , Esther BACHAR-LUSTIG , Assaf LASK , Sivan KAGAN
IPC: C12N5/0783 , C12N5/00 , A61K35/17 , A61K39/00
Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
-
Patent Agency Ranking
公开(公告)号：US20190314312A1
公开(公告)日：2019-10-17
申请号：US16316639
申请日：2017-07-11
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Ayelet EREZ , Noa STETTNER
IPC: A61K31/198 , A61K31/366 , A61P1/00 , A61P35/00
Abstract: Provided are uses of a therapeutically effective amount of citrulline for the manufacture of a medicament for treatment of a subject having an inflammatory bowel disease (IBD) and/or colon cancer. Also provided are pharmaceutical compositions comprising a therapeutic effective amount of citrulline and a therapeutically effective amount of a flavonoid for the treatment of an inflammatory bowel disease (IBD) and/or colon cancer and kits comprising same.
-
公开(公告)号：US10426821B2
公开(公告)日：2019-10-01
申请号：US15636683
申请日：2017-06-29
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irit Sagi , Eitan Wong , Ran Afik
Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
-
公开(公告)号：US10369172B2
公开(公告)日：2019-08-06
申请号：US14367917
申请日：2012-12-20
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yair Reisner , Esther Bachar-Lustig
IPC: A61K35/28 , A61K35/17 , A61K35/22 , A61K35/38 , A61K35/39 , A61K35/407 , A61K35/42 , A61K31/675 , A61K35/34 , A61K35/36 , C12N5/00 , A61K31/198 , A61K31/255 , A61K31/7076 , A61K31/661 , A61K39/395 , A61K39/00 , A61K35/12
Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.
-
公开(公告)号：US20190195891A1
公开(公告)日：2019-06-27
申请号：US16325393
申请日：2017-08-18
Applicant: Yeda Research and Development Co. Ltd.
Inventor： David WALLACH , Andrew KOVALENKO , Seongmin YOON
CPC classification number: G01N33/6893 , A61K35/12 , A61K45/06 , C12Q1/485 , C12Q1/6883 , C12Q1/6888 , C12Q2600/112 , C12Q2600/158 , G01N2800/7095
Abstract: A method of detecting activation of a necroptosis activation pathway in a subject is disclosed. The method comprising: (a) obtaining a biological sample comprising exosomes from the subject; (b) detecting an activity or expression of a component of the necroptosis activation pathway in an exosome fraction of the biological sample, wherein an increase in the activity or expression of the component of the necroptosis activation pathway indicates the activation of said necroptosis activation pathway. Methods of diagnosing necroptosis or inflammation by determining the level of exosomes in a biological sample. Method of modulating endocytosis by inhibiting MLKL or a cell surface receptor and a pharmaceutical composition comprising a population of exosomes comprising a component of the necroptosis activation pathway and its use in therapy of diseases, such as inflammation and cancer.
-
90.发明授权公开(公告)号：US10329347B2
公开(公告)日：2019-06-25
申请号：US14827337
申请日：2015-08-17
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Idit Shachar , Inbal Binsky , Mirko Sobotta
IPC: G01N33/574 , C07K16/28 , C07K14/705 , C12Q1/6886 , A61K38/00
Abstract: A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL.
-
-
-
-
-
-
-
-
-
Search Results
997
records
(took 0.054 seconds)
